Abstract | BACKGROUND: RESULTS: Despite little to no expression in normal ovarian surface epithelium, western immunoblotting, immunohistochemical staining and enzyme linked immunosorbent assay showed elevated RHAMM levels in clinical tissue sections, omental metastasis and urine specimens of serous OC patients, as well as in cell lysates. We also found that RHAMM levels increase with increasing grade and stage in serous OC tissues and that RHAMM localizes to the apical cell surface and inclusion cysts. Apical localization of RHAMM suggested protein secretion which was validated by detection of significantly elevated urinary RHAMM levels (p < 0.0001) in OC patients (116.66 pg/mL) compared with normal controls (8.16 pg/mL). Likewise, urinary RHAMM levels decreased following cytoreductive surgery in OC patients suggesting the source of urinary RHAMM from tumor tissue. Lastly, we validated RHAMM levels in OC cell lysate and found at least 12× greater levels compared to normal ovarian surface epithelial cells. CONCLUSION: This pilot study shows, for the first time, that RHAMM may contribute to OC disease and could potentially be used as a prognostic marker.
|
Authors | Stephanie T Buttermore, Mitchel S Hoffman, Ambuj Kumar, Anne Champeaux, Santo V Nicosia, Patricia A Kruk |
Journal | Journal of ovarian research
(J Ovarian Res)
Vol. 10
Issue 1
Pg. 66
(Sep 27 2017)
ISSN: 1757-2215 [Electronic] England |
PMID | 28954627
(Publication Type: Journal Article)
|
Chemical References |
- Extracellular Matrix Proteins
- Hyaluronan Receptors
- hyaluronan-mediated motility receptor
|
Topics |
- Carcinoma, Ovarian Epithelial
- Disease Progression
- Extracellular Matrix Proteins
(metabolism, urine)
- Female
- Humans
- Hyaluronan Receptors
(metabolism)
- Neoplasm Staging
- Neoplasms, Glandular and Epithelial
(metabolism, pathology)
- Ovarian Neoplasms
(metabolism, pathology)
|